ONTX
(NASDAQ)
0.4176
+0.0141  (+3.37%)
Volume (24h): 11.67M Day Range: 0.4000 - 0.4390
Market Cap: 70.43M 52W Range: 0.1260 - 4.00
May-28-20 01:44PM 3 “Strong Buy” Penny Stocks That Offer Massive Potential GainsTipRanks
May-18-20 03:33PM Edited Transcript of ONTX earnings conference call or presentation 14-May-20 8:30pm GMTThomson Reuters StreetEvents
May-14-20 08:05PM Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial ResultsGlobeNewswire
May-11-20 12:00PM Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of StockholdersGlobeNewswire
May-07-20 12:00PM Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020GlobeNewswire
Apr-27-20 12:00PM Onconova Therapeutics Strengthens Board of Directors with Nomination of Life Sciences Industry VeteranGlobeNewswire
Apr-07-20 10:40AM How 3 Philly-area biopharmaceutical firms are working through coronavirus challengesAmerican City Business Journals
Apr-02-20 11:00AM Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMTThomson Reuters StreetEvents
04:58AM Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Apr-01-20 11:32AM Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMTThomson Reuters StreetEvents
07:30AM Edited Transcript of ONTX earnings conference call or presentation 24-Mar-20 8:30pm GMTThomson Reuters StreetEvents
Mar-24-20 08:05PM Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial ResultsGlobeNewswire
Mar-18-20 12:00PM Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial ResultsGlobeNewswire
Mar-13-20 01:46PM Will Onconova Therapeutics Continue to Surge Higher?Zacks
Mar-02-20 02:54PM Onconova (ONTX) to Report Q4 Earnings: What's in Store?Zacks
Feb-21-20 03:12PM The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and EnnisZacks
Feb-20-20 01:45PM Onconova Therapeutics, Inc. (ONTX) Shares March Higher, Can It Continue?Zacks
12:03PM US Dollar Flexes Muscles Against Other Currencies: 5 WinnersZacks
Feb-19-20 04:19PM The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona TherapeuticsZacks
Feb-18-20 03:06PM Coronavirus to Hit Apple Sales: Invest in Domestic ProducersZacks
02:21PM Coronavirus to Hit Apple Sales: Invest in Domestic ProducersZacks
Feb-18-20 01:00PM Onconova Therapeutics Announces Participation in Two Upcoming International ConferencesGlobeNewswire
Feb-10-20 01:00PM Onconova Therapeutics to Present Update at Noble Capital Markets’ Sixteenth Annual Investor Conference in Hollywood, FLGlobeNewswire
Feb-04-20 01:00PM Onconova Therapeutics to Present Update at the 2020 BIO CEO & Investor Conference in New York CityGlobeNewswire
Jan-23-20 10:44PM Onconova shares rise after company regains rights to drug in ChinaAmerican City Business Journals
01:30PM Onconova Therapeutics Regains Rigosertib Rights in Greater ChinaGlobeNewswire
Jan-03-20 06:27PM Onconova Therapeutics, Inc. Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-MarketGlobeNewswire
Jan-02-20 06:48PM Bucks County biopharm firm plans $10M stock saleAmerican City Business Journals
Dec-31-19 04:30PM Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-MarketGlobeNewswire
Dec-24-19 12:33AM Onconova Therapeutics, Inc. (ONTX) Is Burning These Hedge FundsInsider Monkey
Dec-19-19 06:44PM Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-MarketGlobeNewswire
Dec-18-19 02:05PM Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewswire
02:00PM Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New ZealandGlobeNewswire
Dec-17-19 12:30PM Onconova Therapeutics and Pint Pharma Announce Brazilian Health Authority Approval for Initiating INSPIRE Trial with Intravenous Rigosertib in Higher-Risk Myelodysplastic Syndromes in BrazilGlobeNewswire
Dec-10-19 08:07PM Onconova Therapeutics, Inc. Announces Closing of $5.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewswire
Dec-09-19 02:00PM Onconova Therapeutics Announces Data on Genomic Profiles of Higher Risk Myelodysplastic Syndromes Patients Refractory to Azacitidine Therapy Enrolled into the Pivotal INSPIRE Trial and Updated Oral Rigosertib Data Informing a Potential Adaptive Clinical Trial Design at the American Society of Hematology 2019 Annual MeetingGlobeNewswire
01:00PM Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-MarketGlobeNewswire
Dec-07-19 01:35PM The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom RulingBenzinga
Dec-06-19 01:49PM Benzinga Pro's Top 5 Stocks To Watch For Fri., Dec. 6, 2019: TSLA, ONTX, XHB, BIG, SFIXBenzinga
12:30PM Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the USGlobeNewswire
Nov-25-19 02:26PM Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public OfferingGlobeNewswire
Nov-22-19 07:46PM Bucks County biopharm firm enters into licensing deal, embarks on stock saleAmerican City Business Journals
Nov-21-19 04:23PM Onconova Therapeutics, Inc. Announces $11.0 Million Public OfferingGlobeNewswire
03:16PM Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in CanadaGlobeNewswire
Nov-07-19 12:30PM Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & ExpositionGlobeNewswire
Oct-24-19 11:30AM Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development UpdateGlobeNewswire
Sep-24-19 12:12PM The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse MergerBenzinga
Sep-23-19 12:52PM Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common StockGlobeNewswire
Sep-19-19 11:39AM The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPOBenzinga
Sep-18-19 02:05PM Onconova Therapeutics Announces Termination of Proposed Public OfferingGlobeNewswire
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division. The company has a license agreement with SymBio Pharmaceuticals Limited; a development and license agreement with Baxter Healthcare SA; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)